To summarize, while it is already clear that GLP-1–based therapies will be an integral part of the treatment of DKD owing to their metabolic, cardiovascular, and kidney effects, exciting times lie ahead, with the ongoing development of compounds that will have potentially greater effects on these outcomes, due to more pronounced effects on body weight and glycemia. This evidence concerns the gene GLP1R and diabetic kidney disease.